Drugs / PrP-siRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07444580 | May 2026 → Aug 2029 expected | prion disease | Broad Institute of MIT and Harvard | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PrP-siRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07444580 ↗ |
| Modality | Small interfering RNA (siRNA) | “Intrathecally administered divalent siRNA designed to target the PRNP mRNA.” NCT07444580 ↗ |
| Route | Intrathecal | “Intrathecally administered divalent siRNA” NCT07444580 ↗ |
| Target | PRNP | “designed to target the PRNP mRNA” NCT07444580 ↗ |